Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Jane M. Grant-Kels MD, FAAD Advisory Board

Eliot N. Mostow MD, MPH Associate Editor

Robert T. Brodell MD, FAAD Editor-in-Chief

See All Experts

featured

Published in Dermatology and

Journal Scan / Research · February 03, 2021

Clinical Utility of Skin Cancer and Melanoma Risk Scores for Population Screening

Journal of the European Academy of Dermatology and Venereology: JEADV

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Viola Franke MD

Justin Marson MD

Journal of the European Academy of Dermatology and Venereology: JEADV

Clinical Utility of Skin Cancer and Melanoma Risk Scores for Population Screening: TRoPICS Study

J Eur Acad Dermatol Venereol 2020 Dec 03;[EPub Ahead of Print], A Shetty, M Janda, K Fry, S Brown, B Yau, L Von Schuckmann, S Thomas, JE Rayner, L Spelman, G Wagner, H Jenkins, K Lun, J Parbery, HP Soyer, RE Neale, AC Green, DC Whiteman, CM Olsen, K Khosrotehrani

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Melanoma

Clinical Utility of Skin Cancer and Melanoma Risk Scores for Population Screening

Additional Info

Clinical Utility of Skin Cancer and Melanoma Risk Scores for Population Screening: TRoPICS Study

Further Reading

Outcomes of Field-Directed Photodynamic Therapy Using BF-200 ALA in Patients With Actinic Keratosis

Patient Preferences Regarding the Treatment of Bowen's Disease

Cost-Utility Analysis of Clinic-Based Deroofing vs Local Excision for Hidradenitis Suppurativa

Assessing the Strategies Used to Improve Patient Diversity in a Novel Psoriasis Study

Clinical Presentation, Diagnosis, and Management of Drug Reaction With Eosinophilia and Systemic Symptoms

Association of Gabapentinoid Use With Risk of Hip Fracture

Outcomes of Continued Ritlecitinib Treatment Through Week 48 in Patients With Alopecia Areata With or Without Early Target Responses

Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Initially Treated With Baricitinib 4 mg

Clinical Safety and Efficacy of Dual-Wavelength Low-Level Light Therapy Among Patients With Androgenetic Alopecia

Efficacy of Treatment With Bimekizumab in Patients With Hidradenitis Suppurativa

Efficacy and Safety of Treatment With Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis

Recently Updated